2015
DOI: 10.1038/nature15542
|View full text |Cite
|
Sign up to set email alerts
|

Selective small-molecule inhibition of an RNA structural element

Abstract: Riboswitches are non-coding RNA structures located in messenger RNAs that bind endogenous ligands, such as a specific metabolite or ion, to regulate gene expression. As such, riboswitches serve as a novel, yet largely unexploited, class of emerging drug targets. Demonstrating this potential, however, has proven difficult and is restricted to structurally similar antimetabolites and semi-synthetic analogues of their cognate ligand, thus greatly restricting the chemical space and selectivity sought for such inhi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
381
0
8

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 333 publications
(395 citation statements)
references
References 52 publications
6
381
0
8
Order By: Relevance
“…Indeed, efforts to create novel compounds that bind riboswitches have yielded antibacterial efficacy (Kim et al 2009;Mulhbacher et al 2010;Blount et al 2015;Howe et al 2015), although some of these compounds might use broader mechanisms to inhibit bacterial growth (Kim et al 2009;Kofoed et al 2016). The distribution of riboswitches among various divisions of bacteria (Fig.…”
Section: Phylogenetic Distributions Of Riboswitchesmentioning
confidence: 99%
“…Indeed, efforts to create novel compounds that bind riboswitches have yielded antibacterial efficacy (Kim et al 2009;Mulhbacher et al 2010;Blount et al 2015;Howe et al 2015), although some of these compounds might use broader mechanisms to inhibit bacterial growth (Kim et al 2009;Kofoed et al 2016). The distribution of riboswitches among various divisions of bacteria (Fig.…”
Section: Phylogenetic Distributions Of Riboswitchesmentioning
confidence: 99%
“…Moreover, phenotypic screens can be used to uncover unexpected mechanisms by which small molecules modulate a target or pathway (such as by binding to and modifying a regulatory RNA structure) (24). Further, beyond small molecules and monoclonal antibodies, new therapeutic modalities are gaining traction, such as mRNA delivery, small interfering RNA and antisense oligonucleotides, gene editing with CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9, and peptides.…”
Section: Therapeutic Modulationmentioning
confidence: 99%
“…Several studies have demonstrated that riboswitches are indeed druggable [6–8,16,47–49]. The most prominent investigation employed a phenotypic screen and identified ribocil that acts as a structurally distinct mimic of the natural ligand flavin mononucleotide to repress ribB gene expression and inhibit cell growth [7]. …”
Section: Discussionmentioning
confidence: 99%